Bayer HealthCare

Sector in which the organization works:


Short description of the organization and its work to control and eliminate NTDs

Bayer HealthCare Pharmaceuticals is the pharmaceutical division of Bayer HealthCare AG. We market our products in more than 100 countries; more than 37,000 members of staff currently work for Bayer HealthCare Pharmaceuticals worldwide – more than 6,500 in research and development alone. We aim to improve people’s quality of life with our products. We would like all people to share the fruits of medical progress, regardless of their origins or income. We support programs that provide access to innovative medicines and take up the fight against neglected tropical diseases. We support the fight against NTDs by supplying live-saving drugs for Chagas disease and African sleeping sickness patients to the WHO.

The widespread West African form of African sleeping sickness can be effectively treated with a therapy combining two active substances: Bayer HealthCare's nifurtimox and eflornithine from another manufacturer. After completion of clinical trials in 2009, the new combination therapy was added to the WHO's List of Essential Medicines. Since then, Bayer HealthCare has supplied the WHO with 400,000 nifurtimox tablets a year. In addition, the company has been providing suramin in the necessary amounts since 2002, which is also on WHO's List of Essential Medicines. Suramin is used to treat people infected with the parasite Trypanosoma brucei rhodesiense, which occurs mainly in Eastern and Southern Africa.

To treat Chagas disease, Bayer HealthCare supplies the WHO with a drug containing an active ingredient called nifurtimox. Nifurtimox is on WHO’s list of "Essential Medicines." Bayer Healthcare, the only manufacturer of nifurtimox worldwide, guarantees the availability of the drug. Since 2004 Bayer HealthCare has been supporting the WHO in the fight against Chagas disease with drugs and financial assistance for logistics and distribution. In 2011 the agreement was renewed early, doubling the number of tablets provided to 1 million per year. Above that, Bayer HealthCare is giving access to selected substances to third parties, including DNDi, out of its compound libraries to find new treatments for NTDs.

Bayer HealthCare is one of the 20 original endorsers of the London Declaration

Program Name

Support of fight against Chagas disease and African sleeping sickness